Biogen Inc.

Equities

BIIB

US09062X1037

Real-time Estimate Cboe BZX Other stock markets 11:55:36 2025-12-15 am EST			5-day change	1st Jan Change
173.88 ^USD	-0.12%		-3.59%	+13.76%

Dec. 12	Bitcoin hoarding company Strategy remains in Nasdaq 100	RE
Dec. 12	Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index	RE

Transcript : Biogen Inc. Presents at Wedbush Rewind ASN 2025 Conference, Nov-10-2025 11

Published on 11/10/2025 at 02:50 pm EST - Modified on 11/10/2025 at 04:25 pm EST

S&P Capital IQ

Presenter Speech
Laura Chico (Analysts)

Well, thank you, everybody, for joining me at the next presentation in our Wedbush ASN Rewind. My name is Laura Chico. I'm one of the senior biotech analysts

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Biogen Inc.

Dec. 12	Bitcoin hoarding company Strategy remains in Nasdaq 100	RE
Dec. 12	Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index	RE
Dec. 12	Morgan Stanley Adjusts Biogen Price Target to $156 From $149, Maintains Equalweight Rating	MT
Dec. 12	Alzheimer's drug hunt learns from cancer fight's multi-target playbook	RE
Dec. 12	Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	RE
Dec. 12	PREVIEW-Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	RE
Dec. 10	This Is Decision Day
Dec. 10	Wells Fargo Adjusts Price Target on Biogen to $190 From $155, Maintains Equalweight Rating	MT
Dec. 10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
Dec. 10	HSBC Downgrades Biogen to Reduce From Hold, Adjusts Price Target to $143 From $144	MT
Dec. 05	Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	CI
Dec. 05	Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen	RE
Dec. 05	Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen	RE
Dec. 04	Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option	MT
Dec. 03	Eisai Co., Ltd. and Biogen Inc. Present New Data	CI
Dec. 03	Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment	RE
Dec. 03	Health Care Up on Alzheimer's Hopes - Health Care Roundup	DJ
Dec. 03	Biogen Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 11:30 AM
Dec. 02	Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference	MT
Dec. 02	Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025	CI
Dec. 02	Biogen Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 12:55 PM
Dec. 01	Tyra Biosciences, Inc. Appoints Heather Faulds as Chief Regulatory Officer, Effective December 8, 2025	CI
Nov. 28	Sector Update: Health Care Stocks Mixed Premarket Friday	MT
Nov. 28	Sector Update: Health Care	MT
Nov. 28	Biogen, Eisai Seek Japan Approval for Alzheimer's Drug At-Home Injection	MT